60 Degrees Pharmaceuticals (SXTP) and Tufts Medical Center said Monday that they signed a patent license agreement to jointly advance development and commercialization of tafenoquine for the treatment and prevention of babesiosis.

Under the deal, the companies with co-own patent applications related to tafenoquine for babesiosis, while 60 Degrees will hold exclusive global rights to commercialize the product and Tufts will receive royalties on net sales.

60 Degrees said it is the sponsor of a trial evaluating tafenoquine in treating severe babesiosis, for which enrollment is ongoing. The study's main study endpoints are the time to sustained clinical resolution of symptoms and time to molecular cure as determined by an FDA-approved nucleic acid test, according to the company.

Price: 1.17, Change: -0.10, Percent Change: -7.54